Use of the comet test in the evaluation of multidrug resistance of human cell lines.
The comet test is a reported method for measuring DNA damage in individual mammalian cells. In the present report, the ability of this test to detect multidrug resistance (MDR) was evaluated. For this purpose, two human leukemia, well-characterized parental cell lines, HL60 and CEM, and their derived multidrug-resistant cells, HL60/DNR and CEM/VBL, were cultured with or without different anti-cancer agents. To evaluate the comet test, two DNA-damaging agents were used: daunorubicin (DNR), which is involved in MDR, and ambamustine (AMBA), which is independent from MDR. Moreover, in order to evaluate the specificity of the comet test, the activity of vinblastine (VBL), an MDR-related, DNA-independent anti-cancer drug, was also tested. Finally, the specificity of the comet test in detecting MDR was confirmed by culturing parental or resistant cells with DNR with or without the revertant agent verapamil (VER). Results confirm that the comet test is able to predict cellular chemoresistance when DNA damaging agents are tested. Finally, experiments on the role of the comet test in evaluating certain aspects of DNA repair are discussed.
Mattii
L
L
UO Ematologia, Università di Pisa, Italy.
Barale
R
R
Petrini
M
M
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D004249:DNA Damage; D004260:DNA Repair; D004273:DNA, Neoplasm / Q000032:analysis; D003630:Daunorubicin / Q000494:pharmacology; D018432:Drug Resistance, Multiple; D004586:Electrophoresis / Q000379:methods*; D018922:HL-60 Cells / Q000187:drug effects; D006801:Humans; D015458:Leukemia, T-Cell / Q000188:drug therapy; D014407:Tumor Cells, Cultured
D000903:Antibiotics, Antineoplastic; D004273:DNA, Neoplasm; D003630:Daunorubicin